CCR presentations at AACR 2019

A number of CCR scientists will present their research at the AACR Annual Meeting in Atlanta, between March 29 - April 3, 2019. Selected oral presentations are listed below. A full list of abstracts can be found on the AACR website.

Saturday, March 30, 2019

Time Title Authors Session
10:15 AM - 10:40 AM Neutrophil adaptation to the cancer niche Daniel McVicar ED26 - Diverse Functions of Neutrophils in Cancer

Sunday, March 31, 2019

Time Title Authors Session
2:00 PM - 2:05 PM HTAN program overview Philipp Oberdoerffer NIH03 - Towards the Generation of Spatial Human Tumor Maps

Monday, April 1, 2019

Time Title Authors Session
11:30 AM - 11:50 AM Training opportunities in NCI Intramural Programs Jonathan Wiest NIH06 - NCI-Sponsored Training Awards and Opportunities
11:05 AM - 11:30 AM The microbiome in cancer therapy Giorgio Trinchieri SY14 - The Microbiome as an Orchestrator of Immunity and Cancer Immunotherapy
11:39 AM - 12:02 PM Phase I evaluation of M7824, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus (HPV)-associated malignancies Julius Strauss CTPL03 - Optimizing PD-1/PD-L1 Immune Checkpoint Inhibitor Therapy: Dedicated to the Memory of Waun Ki Hong
1:30 PM - 1:50 PM SY45-02 - Harnessing genetic interactions to advance whole-exome precision cancer treatment Eytan Ruppin SY45-313 - The Next Generation of Precision Cancer Medicine: Recognizing and Exploiting the Complexity
1:30 PM - 1:55 PM The evolution of CAR-T cell based immunotherapy in hematologic malignancies Nirali Shah AOS02 - Emerging Immunotherapies for Childhood Cancer
1:45 PM - 2:00 PM MyPART: Engaging rare tumor patients and their families in rare tumor research Karlyne Reilly NIH08 - New NCI Collaborative Initiatives on Rare Tumors and RASopathies
2:00 PM - 2:15 PM RASopathies: Natural history study and plans for interventional clinical trials Marielle Yohe NIH08 - New NCI Collaborative Initiatives on Rare Tumors and RASopathies
1:50 PM - 2:10 PM Strategies to overcome resistance to targeted therapy of lymphoma based on functional genomic and chemical screens Louis Staudt SY42 - Dharma Master Jiantai Symposium in Targeted Therapy: Systematic Elucidation of Nononcogene Targets
6:15 PM - 6:30 PM From first-in-human to FDA approval in 4 years: The power of partnering with the NCI James Gulley NIH10 - NCI Innovations as a Key Driver of New Company Formation and Early-Stage Technologies
6:15 PM - 6:45 PM Harnessing immune plasticity in the metastatic niche Rosandra Natasha Kaplan SS01 - Joint Cancer Immunology (CIMM) / Tumor Microenvironment (TME) Working Groups Evening Scientific Session

Tuesday, April 2, 2019

Time Title Authors Session
8:25 AM - 8:50 AM T-cell therapy targeting unique cancer mutations Steven Rosenberg PL03 - Manipulating the Immune System in Cancer Therapy
2:00 PM - 2:25 PM Targeting the genetic and metabolic basis of renal cell carcinoma Marston Linehan AOS07 - Genitourinary, Bladder, and Renal Cancers
3:20 PM - 3:35 PM HNRNPH1-dependent splicing of a fusion oncogene reveals a targetable RNA G-quadruplex interaction Natasha Caplen MS.MCB04.01 - Deregulated Transcription and RNA Processing in Cancer
7:17 PM - 7:25 PM Interferon signaling contributes to prostate cancer self-renewal and therapy resistance Supreet Agarwal TM04 - Tumor Microenvironment Working Group (TME) Town Hall Meeting and Networking Reception